Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report

doi:10.12998/wjcc.v7.i5.616

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7336)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

406

WORD

203

HTML

2759

Figures (1-2)

240

Tables (1-1)

210

Sum=3818

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

782

Download

735

Sum=1517

Publishing Process of This Article

Item

Count

Browse

742

Download

1259

Sum=2001

Mar 6, 2019 (publication date) through Nov 12, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Mar 6, 2019; 7(5): 616-622
Published online Mar 6, 2019. doi: 10.12998/wjcc.v7.i5.616

Table 1 Outcome of single-agent epidermal growth factor receptor tyrosine kinase inhibitor studies in recurrent/metastatic squamous cell carcinoma of head and neck

Agent	Phase/publication	Control arm	RR (%)	OS (mo)
Erlotinib	II/Soulieres[8]	None	4.3	6
Lapatinib	II/de Souza[11]	None	0	9.6-5.2 (lower on prior EGFR inhibitor exposure)
Gefitinib	III/Stewart[9]	Methotrexate	2.7 (250 mg/d); 7.6 (500 mg/d)	5.6 (250 mg/d); 6 (500 mg/d)
Afatinib	III/Machiels[10]	Methotrexate	10	6.8

RR: Response rate; OS: Overall survival; EGFR: Epidermal growth factor receptor.

Citation: Thinn MM, Hsueh CT, Hsueh CT. Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report. World J Clin Cases 2019; 7(5): 616-622
URL: https://www.wjgnet.com/2307-8960/full/v7/i5/616.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i5.616